Financing channel feed – Endpoints News

Financing channel feed

Lonza to invest $500M+ on fill-finish facility on its home turf

3 years ago

Small Massachusetts biotech tries to beat back the bears with $55M PIPE

3 years ago

With chance to take on Bristol Myers' $13B heart drug, Cytokinetics preps for pivotal studies with $450M debt raise

3 years ago

Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch

3 years ago

What bear market? Blueprint lines up $1.25B to expand labels, maybe tack on more drugs

3 years ago

Fujifilm invests another $1.6B into its CDMO arm to upgrade facillites in the US and Europe

3 years ago

Sid Mukherjee, Lew Cantley behind new cancer biotech with food+drug combo treatment ambitions

3 years ago

With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug

3 years ago

Updated: As bear market continues to beat down biotech, ARCH closes a $3B early-stage fund

3 years ago

Pfizer, Sanofi-backed LNP outfit goes back to the well and draws $120M for its trek to the clinic

3 years ago

Oxford spinout nabs almost $100M in new cash to test PD-1 in autoimmune diseases and hunt for a CEO

3 years ago

Alexion puts €65M forward to strengthen its position on the Emerald Isle

3 years ago

A Merck partner is sucked into the financial quagmire as key lender calls in a note

3 years ago

Biden and G7 nations offer funds for vaccine and medical product manufacturing project in Senegal

3 years ago

VC firms take osteoporosis drugmaker Radius Health private for almost $900M

3 years ago

Scoop: Little-known OrbiMed-backed biotech closes $160M round to start gene therapy trial

3 years ago

EU to launch vaccine development and manufacturing partnership with Latin American and Caribbean countries

3 years ago

Xenon jumps on positive data-to-immediate public offering train to bankroll PhIII epilepsy study

3 years ago

Longwood sets another 'don't eat me' biotech into gear with help of former Trillium CEO Jan Skvarka

3 years ago

Alladapt gets $100M+ to see its all-in-one oral immunotherapy allergy drug through clinical trials

3 years ago

Human Longevity makes a move toward Nasdaq with potential SPAC deal, but nothing's final yet

3 years ago

Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field

3 years ago

Pfizer nabs $95M stake in Valneva as Lyme disease vaccine approaches pivotal study

3 years ago

In attempted bear market brushback, SMA player Scholar Rock nabs $205M raise on open-label extension data

3 years ago

First page Previous page 51 52 535455 56 57 Next page Last page